The city-based drug maker's PAT was down to 59.1 crore in the quarter ended June 30, as against Rs 126.3 crore in the same quarter last year, it said.
As per Indian accounting standards (Ind AS), the consolidated net profit during the quarter was 66.6 crore as against Rs 153.5 crore during the corresponding quarter last year, a statement from Dr Reddy's said.
The company's co-chairman and CEO, G V Prasad, said the results were below their expectations.
"Our first quarter results of FY18 have been below expectations. While headwinds in the form of price erosion due to the US customer consolidation continue, a lower contribution from new product launches in the US and the GST implementation in India also impacted our performance," Prasad said.
He, however, said the positive side of the results is they are in their journey of quality maintenance, as several inspections by the US FDA teams have successfully completed.
The sale of generics from North America was down by 4 per cent to Rs 1,495 crore in Q1 of FY18 against Rs 1,552 crore in the same quarter last year.
The sale from Indian market was negatively impacted by 10 per cent to Rs 469 crore against Rs 522 crore in Q1 FY17.
The revenue from pharmaceutical services and active ingredients stood at Rs 465 crore, marginally down by 1 per cent.
As on June 30, 99 generic filings were pending before the US FDA , of which 97 are ANDAs (including 59 Para-IV filings).
The shares of Dr Reddy's were trading at Rs 2,643.85, down 2.46 per cent, on BSE at 1453 hrs.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
